SCHEDULE 13D: Redmile Group Boosts Stake in Atara Biotherapeutics, Appoints Director to Board

Investment firm Redmile Group, LLC and its affiliates have significantly increased their beneficial ownership in Atara Biotherapeutics, Inc. to 9.9%, concurrently securing a board seat for managing director Nachi Subramanian.

Summary

• Redmile Group, LLC and its affiliates (Jeremy C. Green, RedCo I, L.P., and Redmile Biopharma Investments II, L.P.) reported beneficial ownership of 705,207 shares of Atara Biotherapeutics, Inc. common stock, representing 9.9% of the outstanding class.
• This ownership includes 441,701 shares directly held by Redmile Funds and 263,506 shares issuable upon exercise of pre-funded warrants, subject to a 9.99% beneficial ownership limitation.
• The Redmile Funds acquired new pre-funded warrants to purchase 680,796 shares of common stock for approximately $4,499,993 in an underwritten registered offering that closed on May 16, 2025.
• The purpose of the transaction is for investment, with Redmile Group intending to monitor the investment and potentially discuss strategic alternatives, including changes to the Board or management, to increase stockholder value.
• Nachi Subramanian, a managing director of Redmile, was appointed to Atara Biotherapeutics' Board of Directors on May 16, 2025, and has waived his right to receive compensation for his board service.
• As of May 7, 2025, Atara Biotherapeutics had 5,961,391 shares of common stock outstanding, with an additional 834,237 shares issued in the Registered Offering.
• Redmile Funds also hold cash-settled swap agreements representing 8,975 notional shares, or approximately 0.13% of outstanding common stock, which do not confer voting or dispositive control.

Sentiment

Score: 7

Explanation: The filing indicates a significant vote of confidence from a specialized investor, Redmile Group, through a substantial investment and board representation. This suggests a belief in the company's long-term potential. However, the potential for activist investor actions and dilution from the offering introduce some caution.

Positives

• Significant investment by a specialized biopharma investor (Redmile Group) signals confidence in Atara Biotherapeutics' future prospects.
• Appointment of Nachi Subramanian, a managing director of Redmile, to the Board of Directors provides Redmile Group with direct influence and oversight, potentially aligning interests for shareholder value creation.
• Mr. Subramanian's waiver of compensation for board service demonstrates a focus on long-term value rather than short-term personal gain.

Negatives

• The registered offering, while raising capital, involves the issuance of new shares and warrants, which can lead to dilution for existing shareholders.
• The stated purpose of potentially considering changes to the Board or management suggests Redmile Group may pursue an activist role if they believe current strategies are not maximizing shareholder value.

Risks

• Beneficial Ownership Limitation: The terms of the pre-funded warrants include a 9.99% beneficial ownership limitation, restricting the immediate exercise of all warrants and potentially limiting Redmile's ability to fully convert its holdings into common stock without prior notice.
• Activist Investor Risk: Redmile Group's stated intention to monitor the investment and potentially discuss changes to the Board or management could lead to future activist campaigns or disagreements with current management.
• Dilution Risk: The issuance of new shares and warrants in the registered offering could dilute the ownership percentage and earnings per share for existing shareholders.

Future Outlook

The reporting persons acquired the securities for investment purposes and will routinely monitor various investment considerations, including the Issuer's operations, assets, prospects, and management. They expect to discuss their investment with the Issuer's Board, management, and other stakeholders, potentially leading to consideration of alternatives to increase stockholder value, including changes in the Board or management. They also reserve the right to acquire or dispose of additional securities.

Industry Context

This filing indicates a significant investment by Redmile Group, a specialized biopharma investment firm, in Atara Biotherapeutics, a biotechnology company. Such investments are common in the biotech sector, where companies often require substantial capital for research and development and clinical trials. The appointment of a managing director from the investment firm to the board suggests a hands-on approach, which can be a trend in biotech where investors seek to actively guide strategic direction given the high-risk, high-reward nature of the industry.

Comparison to Industry Standards

• Redmile Group is a known investor in the biopharma space, and their significant stake (9.9%) is a substantial position for an institutional investor in a biotech company, indicating a strong conviction.
• The acquisition of pre-funded warrants is a common financing mechanism in the biotech industry, allowing companies to raise capital while managing immediate dilution and providing investors with flexibility regarding ownership thresholds.
• The inclusion of a 'Beneficial Ownership Limitation' (9.99%) in warrant terms is a standard protective measure to prevent an investor from triggering certain regulatory thresholds (e.g., 10% ownership requiring additional filings or potentially triggering poison pill provisions) without explicit intent or notice.
• The appointment of an investor's representative to the board is a common practice when an investor takes a significant stake, providing direct oversight and influence, similar to how other large institutional investors or venture capital firms might engage with their portfolio companies.

Management Changes

Corporate Governance

Related Party Transactions

• Nachi Subramanian, a managing director of Redmile Group, LLC, was appointed to the Board of Directors of Atara Biotherapeutics, Inc. on the same day Redmile Group's affiliated funds completed a significant investment.
• Redmile Group, LLC and its affiliated funds (RedCo I, L.P. and Redmile Biopharma Investments II, L.P.) are the reporting persons who made the significant investment in Atara Biotherapeutics.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if Redmile Group's strategic involvement leads to positive changes; potential dilution from the registered offering; potential for activist actions.
• Management: May face increased scrutiny and potential pressure for strategic changes from Redmile Group.
• Employees: No direct impact mentioned, but strategic shifts could indirectly affect employees.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Redmile Group will routinely monitor investment considerations, including the Issuer's operations, assets, prospects, business development, markets, capitalization, management, and competitive/strategic matters.
• Redmile Group expects to discuss their investment in Atara Biotherapeutics with the Issuer's Board of Directors, management, other investors, and industry analysts.
• Redmile Group may consider various alternatives with respect to their investment, including possible changes in the present Board of Directors and/or management of the Issuer or other alternatives to increase stockholder value.
• Redmile Group may acquire additional Issuer securities or dispose of existing holdings in the public markets or privately.
• Nachi Subramanian will serve on the Board of Directors until the 2027 annual meeting of stockholders or until his successor is elected.

Key Dates

Recommendation

Keywords

Atara Biotherapeutics, Redmile Group, Schedule 13D, Beneficial Ownership, Pre-funded Warrants, Registered Offering, Board Appointment, Biotechnology Investment, Shareholder Activism, ATRA